Life Science

Global Alosetron Production Market Share, Revenue, and Average Price by Manufacturers Shared in a Latest Research Report

Alosetron (original brand name: Lotronex; originator: GSK) is a 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in women only. It is currently marketed by Prometheus Laboratories Inc. (San Diego). Alosetron was withdrawn from the market in 2000 owing to the occurrence of serious life-threatening gastrointestinal adverse effects, but was reintroduced in 2002 with availability and use restricted.

Access Report Details at:

The global Alosetron market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.

This report focuses on Alosetron volume and value at global level, regional level and company level. From a global perspective, this report represents overall Alosetron market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.

Key companies profiled in Alosetron Market report are Sebela Pharmaceuticals, Amneal, Par Pharmaceutical, West-Ward Pharmaceuticals and more in term of company basic information, Product Introduction, Application, Specification, Production, Revenue, Price and Gross Margin (2014-2019), etc.

Purchase this Premium Report at:

Table of Content

1 Alosetron Market Overview

2 Global Alosetron Market Competition by Manufacturers

3 Global Alosetron Production Market Share by Regions

4 Global Alosetron Consumption by Regions

5 Global Alosetron Production, Revenue, Price Trend by Type

6 Global Alosetron Market Analysis by Applications

7 Company Profiles and Key Figures in Alosetron Business

8 Alosetron Manufacturing Cost Analysis

9 Marketing Channel, Distributors and Customers

10 Market Dynamics

11 Global Alosetron Market Forecast

12 Research Findings and Conclusion

13 Methodology and Data Source